{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-264085","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-06-09T21:32:31+00:00","discovered_at":"2026-06-10T10:05:00.211265+00:00","generated_at":"2026-06-10T10:05:10.927232+00:00","sec_items":["5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Enliven Therapeutics doubles authorized common shares to 200M, annual meeting votes pass","bullets":["Stockholders approved amendment increasing authorized common shares from 100M to 200M; effective June 9, 2026.","Elected Class III directors Richard Fair and Lori Kunkel with 99.7% and 64.7% of votes cast, respectively.","Ratified Deloitte & Touche as independent auditor for FY2026 with overwhelming support (56.1M for).","Advisory say-on-pay approved (47.6M for, 89.5% of votes cast); advisory vote on frequency set to every one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-264085","json":"https://secwatch.observer/filing/0001193125-26-264085.json","markdown":"https://secwatch.observer/filing/0001193125-26-264085.md","text":"https://secwatch.observer/filing/0001193125-26-264085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/0001193125-26-264085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/d152745d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:05:10.927232+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9890052cb2c276a04d83d1c6257cd572fd1bffcd","claim":"Enliven Therapeutics, Inc.: Increased authorized shares of common stock from 100,000,000 to 200,000,000 (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, following stockholder approval, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000, which amendment was effective as of the date of filing.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526264085/0001193125-26-264085-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}